Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
Status:
Terminated
Trial end date:
2012-06-13
Target enrollment:
Participant gender:
Summary
This study determined the efficacy, safety, tolerability and the PK profile of BAF312, a
novel immunomodulator, in polymyositis and dermatomyositis patients who were not responsive
to traditional immunosuppressive and/or corticosteroid therapy. The study consisted of a 12
week, randomized, placebo controlled period, followed by another 12 weeks where all subjects
received BAF312 treatment.